LIVGEMINI S.R.L.

Every year, cardiovascular diseases cause approximately seventeen million deaths worldwide, and a significant portion of these could be prevented or delayed with more precise diagnoses and more accurate surgical planning. The challenge is that the human heart is a dynamic, complex system: traditional clinical imaging offers a static snapshot of an organ in constant motion, and preoperative decisions are often based on approximate models. LIVGEMINI S.R.L., a Viterbo-based startup, aims to change this paradigm with cardiac digital twins. The technology at the heart of LIVGEMINI's offering is in-silico simulation: three-dimensional, dynamic digital models of an individual patient's heart, built from real clinical data — imaging, hemodynamic measurements, physiological parameters. These digital twins allow cardiologists and surgeons to simulate the patient's specific cardiac behavior under different conditions, test the effect of various interventions before operating, and identify critical areas with greater precision. The potential clinical impact is significant. Simulation-based preoperative planning reduces the risk of complications, shortens intervention times, and improves patient outcomes. For cardiology centers treating the most complex cases — such as congenital malformations or structural heart disease — having a patient-specific simulation tool represents a qualitative leap beyond standardized anatomical models. The business model is B2B, targeting hospitals, specialized cardiology centers, and cardiovascular device companies looking to integrate digital simulation into their diagnostic and surgical workflows. The advanced medical technology market is growing strongly, fueled by public and private investment in healthcare innovation and the increasing regulatory acceptance of software as a medical device. LIVGEMINI is part of an innovation movement — precision cardiovascular medicine — that has the potential to redefine standards of care for millions of patients globally.